Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE PHENYLEPHRINE HYDROCHLORIDE W CODEINE PHOSPHATE versus SYPRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE PHENYLEPHRINE HYDROCHLORIDE W CODEINE PHOSPHATE versus SYPRINE.
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE vs SYPRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, sedative, and antiemetic via central dopamine D2 and muscarinic M1 receptor blockade. Phenylephrine is a sympathomimetic amine that acts as a selective α1-adrenergic receptor agonist, causing vasoconstriction. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects, partly after O-demethylation to morphine.
Syprine (trientine hydrochloride) is a chelating agent that forms stable complexes with copper, thereby increasing urinary excretion of copper and reducing pathological copper accumulation in tissues.
Each 5 mL of oral solution contains promethazine hydrochloride 6.25 mg, phenylephrine hydrochloride 5 mg, and codeine phosphate 10 mg. Adult dose: 5 mL every 4 to 6 hours as needed. Maximum 30 mL per day.
250 mg to 500 mg orally 4 times daily, maximum 2000 mg daily.
None Documented
None Documented
Promethazine: 9-16 h (adults); prolonged in hepatic impairment. Phenylephrine: 2-3 h (oral); 5-10 min (IV due to rapid redistribution). Codeine: 2.5-3.5 h; active metabolites (morphine) 2-3 h.
Approximately 48 hours in healthy subjects, reflecting prolonged accumulation with regular dosing, requiring careful monitoring for toxicity.
Promethazine: ~70% renal as metabolites, minor biliary/fecal. Phenylephrine: ~86-96% renal as metabolites (sulfate and glucuronide conjugates). Codeine: ~90% renal, primarily as morphine and norcodeine conjugates; 5-10% unchanged. Fecal excretion minimal.
Primarily renal (approximately 50% unchanged within 24 hours after oral administration); biliary/fecal elimination accounts for a minor fraction (less than 10%).
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine